3 billion injections! Osaikang, Longtian the same day over the evaluation of AstraZeneta lost half a wall

Medicine Network January 13th, January 12th, the official website of the State Drug Administration shows that Jiangsu Osaikang Pharmaceuticals' injection of Esomeladium sodium and Langtian Pharmaceuticals' injection of Esomeladium sodium to supplement the application was approved on the same day.
, Hunan Cylon Pharmaceuticals' injection of Esomerazole sodium to mimic 4 categories of production was approved, as reviewed.
2019, sales of injections at the end of China's public medical institutions exceeded 3 billion yuan, according to the Company's internal network data.
so far, five companies have evaluated the injection of Esomerazole sodium.
January 12, 2021 drug approval documents to be received information release data show that Esomerazole is a single L-isomer of omeprazole, belongs to proton pump inhibitors (PPI), can effectively inhibit the secretion of stomach acid, compared with other proton pump inhibitors drugs, with fast, long-lasting, stable acid suppression, less adverse reactions.
sodium esomeprazole for injection has been included in the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2020 edition) Class B drugs.
2020H1 China's public medical institutions terminal Esomerazole (Esso meprazole) injection TOP20 brand pattern Source: China's public medical institutions terminal competition pattern Mienet data show that in recent years in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal Esomerazole injections maintained a growth rate of more than 10%, with sales exceeding 3 billion yuan in 2019 and a year-on-year decline of -1.56% in the first half of 2020, with AstraZenecon accounting for the largest market share.
note that AstraZeneta's market share has fallen rapidly in recent years, from its dominant market in 2015 to below 50 per cent in the first half of 2020, as domestic pharmaceutical companies have gained strength.
Up to now, the injection of Esomerazole sodium has 5 enterprises have been evaluated, among them, Zhengda Tianqing Pharmaceutical Group, Jiangsu Osaikang Pharmaceuticals, Langtian Pharmaceuticals to supplement the application was approved, Chongqing Lemie Pharmaceuticals, Hunan Cylon Pharmaceuticals to copy 4 categories of declared listing was approved, as reviewed.
In addition, Liaoning Haisco Pharmaceuticals, Jiangsu Zhengda Fenghai Pharmaceuticals and other 7 enterprises in the consistent evaluation of supplementary applications in the review and approval (in the drug review center), Shi Pharmaceutical Group Ohyi Pharmaceuticals, Jiangsu Howson Pharmaceuticals, Hainan Beit Pharmaceuticals and other 6 enterprises to copy 4 categories of declarations listed in the review and approval (in the drug review center), after approval is considered the same.
source: official website of the State Drug Administration, Mi net database